Opioid Use After Intensive Care: A Nationwide Cohort Study
- PMID: 33512940
- DOI: 10.1097/CCM.0000000000004896
Opioid Use After Intensive Care: A Nationwide Cohort Study
Abstract
Objective: To describe opioid use after ICU admission, identify factors associated with chronic opioid use after critical care, and determine if chronic opioid use is associated with an increased risk of death.
Design: Retrospective cohort study.
Setting: Sweden including all registered ICU admissions between 2010 and 2018.
Patients: Adults surviving the first two quarters after ICU admission were eligible for inclusion. A total of 265,496 patients were screened and 61,094 were ineligible.
Interventions: Admission to intensive care.
Measurements and main results: Among 204,402 individuals included in the cohort, 22,138 developed chronic opioid use following critical care. Mean opioid consumption peaked after admission followed by a continuous decline without returning to baseline during follow-up of 24 months. Factors associated with chronic opioid use included high age, female sex, presence of comorbidities, preadmission opioid use, and ICU length of stay greater than 2 days. Adjusted hazard ratio for death 6-18 months after admission for chronic opioid users was 1.7 (95% CI, 1.6-1.7; p < 0.001). In the subset of patients not using opioids prior to admission, similar findings were noted.
Conclusions: Mean opioid consumption is increased 24 months after ICU admission despite the lack of evidence for long-term opioid treatment. Given the high number of ICU entries and risk of excess mortality for chronic users, preventing opioid misuse is important when improving long-term outcomes after critical care.
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Conflict of interest statement
Dr. Oldner is currently receiving a grant from the European Society of Intensive Care Medicine Established Investigator Award, The Swedish Carnegie Hero Funds, funds from Karolinska Institutet, and through the regional agreement on medical and clinical research between Stockholm County Council and Karolinska Institutet. He received funding from Sedana Research foundation and support for article research from Carnegie Research Foundation. Dr. Larsson is currently receiving a grant from the Swedish Society of Medicine. The remaining authors have disclosed that they do not have any conflicts of interest.
References
-
- Van Zee A. The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. Am J Public Health. 2009; 99:221–227
-
- Campbell J. Presidential address, speech given at the American Pain Society. Pain Forum. 1996; 5:85–88
-
- Centers for Disease Prevention and Control. The Drug Overdose Epidemic: Behind the Numbers. 2020. Available at: https://www.cdc.gov/drugoverdose/data/index.html . Accessed July 28, 2020
-
- Wilson N, Kariisa M, Seth P, et al. Drug and opioid-involved overdose deaths—United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020; 69:290–297. Available at: https://www.cdc.gov/mmwr/volumes/69/wr/mm6911a4.htm . Accessed July 28, 2020
-
- Breivik H, Stubhaug A. Burden of disease is often aggravated by opioid treatment of chronic pain patients: Etiology and prevention. Pain. 2014; 155:2441–2443
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
